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6/j.bDespite advances in graft-versus-host-disease (GVHD) treatment, it is estimated that overall survival (OS) at
2 years for hematopoietic cell transplantation (HCT) recipients who experience steroid-resistant GVHD is
10%. Among recent therapeutic approaches for GVHD treatment, mesenchymal stromal cells (MSCs) hold
a key position. We describe a multicenter experience of 11 pediatric patients diagnosed with acute or chronic
GVHD (aGVHD, cGVHD) treated for compassionate use with GMP-grade unrelated HLA-disparate donors’
bone marrow-derived MSCs, expanded in platelet-lysate (PL)-containing medium. Eleven patients (aged 4-15
years) received intravenous (i.v.) MSCs for aGVHD or cGVHD, which was resistant to multiple lines of
immunosuppression. The median dose was 1.2  106/kg (range: 0.7-3.7  106/kg). No acute side effects
were observed, and no late side effects were reported at a median follow-up of 8 months (range: 4-18
months). Overall response was obtained in 71.4% of patients, with complete response in 23.8% of cases.
None of our patients presented GVHD progression upon MSC administration, but 4 patients presented
GVHD recurrence 2 to 5 months after infusion. Two patients developed chronic limited GVHD. This study
underlines the safety of PL-expanded MSC use in children. MSC efficacy seems to be greater in aGVHD than
in cGVHD, even after failure of multiple lines of immunosuppression.
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Despite the improvement inHLAmatching technique,
about 50% of HSCT recipients experience acute
GVHD (aGVHD), and only 30% to 50%of them ben-
efit from first-line steroid treatment [1]. Second-line
treatment for steroid-resistant GVHD is not univo-
cally established, and varies according to the recipient
conditions, involved organs, and GVHD stage. Any
immunosuppressive strategy is burdened by increased
infection rate and toxicity, which in turn, augments
treatment-related morbidity and treatment-related
mortality (TRM). Today it is estimated that overall
survival (OS) at 2 years for HSCT recipients who
experience steroid-resistant GVHD is 10% [2].
Among the most recent therapeutic approaches for
GVHD,mesenchymal stromal cells (MSCs) hold a key
position. These are multipotent progenitor cells that
present extensive immunomodulatory properties.
They inhibit T and B cell response by arresting them
in the G0/G1 phase of the cell cycle, prevent mono-
cytes from their antigen-presenting function, and
increase regulatory T cell expansion. Of importance,1293
1294 Biol Blood Marrow Transplant 16:1293-1301, 2010G. Lucchini et al.MSCs are known to escape immune rejection, thus al-
lowing their use in an HLA-mismatched setting [3,4].
The first documentationofMSCclinical efficacy for
GVHDtreatmentwas published in 2004 [5]. Since then,
various trials reported nonhomogeneous results. Differ-
ences in GVHD features and treatment schedules
caused complete MSC response to vary from 15% to
55% of treated patients [6-9]. The largest cohort of
patients reported so far was described in 2008 by Le
Blanc et al. [10]. Fifty-five patients with grade II to IV
aGVHD were treated with MSC infusions of either re-
lated or unrelated origin. Thirty patients had a complete
response, and 9 showed variable grades of GVHD im-
provement. Complete responders had a lower 1-year
TRM and a higher 2-year OS than patients with
partial or no response to MSCs.
Standard conditions for MSC expansion include
the presence of serum, in most instances fetal bovine
serum (FBS). Regulatory guidelines, recommending
avoiding the use of animal additives, have reinforced
a search for possible alternatives. For this reason,
platelet-lysate (PL) is currently used in many centers
for MSC expansion for clinical use. A recent article
from von Bonin and colleagues [11] reported 15% of
complete response and 45% of partial response for
GVHD treatment with the use of bone marrow
(BM)-derived MSCs expanded in PL-containing me-
dium from unrelated HLA-disparate donors [11].
Recent controversial observations come from the
company Osiris (http://www.nature.com/news/2009/
090909/full/news.2009.894.html), declaring the failure
of the Prochymal product (http://investor.osiris.com/re
leasedetail.cfm?ReleaseID5407404), which performed
no more effectively than a placebo in GVHD treatment
in late-stage clinical trials.The same productwas, on the
other hand, more efficacious in treating de novo
aGVHD in adult patients with an initial response rate
of 94% [12]. Moreover, recent data point out that
multiple infusions of prochymal (biweekly infusions of
2 106 cells/kg for 4 weeks, with an additional 4 weekly
infusions after day 28 in patients with a partial response)
wereable toproducea64%response rate inpatientswith
otherwise refractory severe GVHD [13].
Quite contentious opinions are therefore present
today in the literature concerning MSC efficacy. In
the present study, we describe amulticenter experience
of 11 pediatric patients diagnosed with resistant
aGVHD or chronic GVHD (cGVHD) treated with
PL-expanded MSCs for compassionate use on top of
multiple lines of immunosuppressant. All MSC were
expanded in 2 authorized goodmanufacturing practice
(GMP) facilities (Laboratory of Cell therapy
‘‘S. Verri,’’ ‘‘Ospedale San Gerardo,’’ Monza, Italy,
and Laboratory ‘‘G. Lanzani,’’ ‘‘Ospedali Riuniti di
Bergamo,’’ Bergamo, Italy), exclusively by means of
GMP-grade qualified reagents and according to
GMP indications. Our observations in a small set ofpediatric patients seem to confirm a positive effect of
PL-cultured MSCs on various patterns of GVHD,
particularly those with acute skin involvement.METHODS
Patients
Between May 2008, and June 2009, 11 patients
aged 4 to 15 years received MSC intravenous infusions
for aGVHD grade I to IV or cGVHD, which had
proved resistant to multiple lines of immunosuppres-
sants. All patients had developed GVHD after
HSCT from unrelated or related donor, which had
been performed for malignant disease in 8 cases and
nonmalignant diseases in 3 cases. Conditioning regi-
mens and GVHD prophylaxis are described in details
in Table 1.
GVHDwas diagnosed upon clinical evidence in all
patients and confirmed by histology in 1 case (patient
number 8). aGVHD and cGVHD were graded
according to internationally accepted criteria by
physicians at individual centers [14].
All patients received steroid as first-line GVHD
treatment. Further lines of treatment depended on
patients and GVHD characteristics (Table 2a and
Table 2b). All patients had failed at least 2 lines of
treatment before receiving MSCs. All patients contin-
ued to receive ongoing immunosuppressant while
receiving MSCs. Patients 3, 4, and 7 presented skin
aGVHD stage 2 (grade I), which had proven resistant
to 3 lines of treatment; they were therefore considered
eligible to MSC treatment.
At the time the firstMSC infusionwas performed, 4
patients had aGVHD involving skin only (overall grade
I or II), 2 had gut aGVHD (overall grade IV). Two pa-
tients suffered aGVHD grade II to IV involving skin
and gut. Three other patients had cGVHD involving
skin and mucosa and/or liver, overall grade I-III
(Table 2a and 2b).
Seven patients were treated at ‘‘Ospedale San
Gerardo,’’ Monza (Italy), 1 patient was treated at ‘‘Isti-
tuto Giannina Gaslini,’’ Genova (Italy), 1 at ‘‘Centro
Trapianti Cellule Staminali Eritropoietiche Ospedale
Microcitemico,’’ Cagliari (Italy), 1 at ‘‘Divisione di
Ematologia, Universita` Cattolica Sacro Cuore,’’
Roma (Italy), and 1 at ‘‘Istituto Scientifico San Raf-
faele,’’ Milano (Italy). Patients were treated for com-
passionate use. MSC infusion was approved by the
local Ethical Committee, and the competent National
Authorities were notified. Donors and patients, or
their legal guardians, signed written informed consent.Definitions
Patients were evaluated for response at 7 and 28
days after MSC infusion. Because some patients
Table 1. Patients’ Characteristics
Pts Age (Years) Sex Dx
Type of Transplantation
Source
HLA Matching Conditioning Regimen GVHD Prophylaxis
1 5 Female ALL 2nd CR Related
Marrow
8/10
TBI + Cy + VP16 CsA + MTX
2 7 Male ALL 2nd CR Unrelated
Marrow
9/10
TBI+ Cy +VP16 CsA + ATG + MTX
3 11 Male ALL 2nd CR Unrelated
Marrow
10/10
TBI + VP16 CsA + ATG + MTX
4 9 Male ALL 1st CR Unrelated
Marrow
8/10
TBI+VP16 CsA + ATG + MTX
5 15 Female ALL 2nd CR Unrelated
Peripheral
9/10
TBI + VP16 CsA + ATG + MTX
6 12 Male ALL 2nd CR Unrelated
Marrow
8/10
TBI + VP16 CsA + ATG + MTX
7 8 Male ALL 2nd CR Unrelated
Marrow
9/10
TBI + VP16 CsA + ATG + MTX
8 10 Male Fanconi anemia Unrelated
Marrow
9/10
Flu + Cy CsA + ATG + MTX
9 14 Male AML Unrelated
Cord Blood
4/6
Flu + Bu + TT CsA + MMF + ATG
10 4 Male Thalassemia Unrelated
Marrow
9/10
Bu + Cy CsA + PDN + MMF
11 11 Female Thalassemia Related
Marrow
10/10
Bu + Cy CsA + PDN + MTX
ALL, acute limphoblastic leukemia; CR, complete remission; AML, acute myelogenous leukemia; Bu, busulphan; Cy, cyclophosphamide; TT, thiotepa; Flu,
fludarabin; TBI, total body irradiation; VP16, vepeside; CsA, cyclosporine A; PDN, prednison; MTX, methotrexate; MMF, mofetil mycophenolate; ATG,
antitymocyte-globulin; GVHD, graft-versus-host disease.
Biol Blood Marrow Transplant 16:1293-1301, 2010 1295PL-Expanded MSCs for GVHD Treatmentpresented multiple GVHD flares, response rate was
calculated separately considering each single GVHD
episode. We defined a response to be complete as
disappearance of all signs and symptoms of GVHD;
partial response as GVHD improvement of at least 1
stage in single organ scoring, or 1 grade in overall
GVHDscoring, ifmore than 1organwas involved. Sta-
ble disease was defined as no change in GVHD staging
and grading. Progressive disease was defined as wors-
ening of GVHD, intended as either involvement of
new organs or worsening of the previously involved or-
gans. Patients were judged to have responded if they
had either complete or partial response. Responding
patients were defined as temporary responders if they
showed any signs of GVHD reduction at day 17 after
MSC infusion but reflared earlier than 28 days after
MSC therapy. Definitive responders were patients
with stable response 28 days after MSC infusion.MSC Preparation for Clinical Use
MSCs were isolated from unrelated HLA-
mismatched BM donors, after having obtained writteninformed consent from the donors. Clinical-grade
mesenchymal stromal cells were generated under
GMP conditions, as we have recently extensively de-
scribed [15]. Briefly, total nucleated cells were isolated
from the washouts of sealed bone marrow collection
bags and filters, and cells were plated, without further
separation, at 800  103 cells/cm2 in complete me-
dium. Complete medium consists of a-modified-Eagle
medium (a-MEM, Invitrogen, Milano, Italy) supple-
mented with 5% freshly thawed PL and 2 mM L-glu-
tamine (LiStarFish, Milano, Italy). MSC cultures were
detached with triple Select (Invitrogen) when the sub-
confluence was reached and cells were replated at 100
to 200 cells/cm2 up to the final detachment and freez-
ing. The final cell products have been subject to all
quality controls required for clinical use. Release crite-
ria included: lack of detectable microbial contamina-
tion (aerobic or anaerobic bacteria, fungi, and
mycoplasma) according to European pharmacopoeia,
cell viability$90%, endotoxin levels in the final prod-
uct #5 EU/kg, cell characterization with high expres-
sion ($70%) of CD73, CD90, and CD105 and lack
(#10%) of CD14, CD34, CD45, normal karyotype
Table 2a. Patients and Graft-versus-Host Disease (GVHD) Features Prior and After Mesenchymal Stromal Cell (MSC) Infusion
Pat
GVHD Grading
at MSC Infusion
GVHD Treatment
at MSC Infusion
No. of MSC
Infusion/Day
from HCT
Infused MSC
(Dose/kg)
Response
After MSC Infusion Tapering of Immunosuppression GVHD Reflaring Follow-up
1A Chronic overlap syndrome
(skin and mucosae grade III)
Steroid+
MMF+ECP+CsA+
azatioprine
1/
day+ 148
1 x 106/kg Partial response
temporary
Skin and mucosae grade I
Yes, steroid 2 days and CsA
16 days after MSC infusion
Yes, gut GVHD grade II
70 days after MSC infusion
Alive with
chronic
skin and mucosae
GVHD grade II
2A Chronic overlap syndrome
(skin and mucosae grade II)
Steroid+
MMF+ECP+
etanercept+
CsA
1/
day +210
1 x 106/kg Complete response
definitive
No GVHD
Yes, stop steroid 30 days, MMF
tapering 50 days and Etanercept
65 days after MSC infusion
Re-flair of gut, skin, and liver
GVHD grade II 95 days after
MSC infusion
Alive with skin
chronic GVHD grade I
2B Chronic mucosae and
liver grade III
Steroid+
FK506+
budesonide+
etanercept
1/
day +300
1.4 x 106/kg Partial response
temporary
Chronic mucosae and
liver grade II
Yes, stop budesonide and steroid
40 days and etanercept 21 days
after MSC infusion
None
3A Acute skin grade I Steroid+
MMF+CsA+
etanercept
1/
day + 62
1 x 106/kg Complete
response definitive
No GVHD
Yes, steroid stopped 17 days after
MSC infusion
None Alive, no GVHD
4A Acute skin grade I Steroid+MMF+CsA+
etanercept
1/
day +34
0.7 x 106/kg No response
Skin GVHD grade I
Stopped Etanercept, but for concomitant
infection 18 days after MSC infusion
GVHD persistance Alive, no GVHD
4B Chronic skin and liver
grade III
Steroid+
CsA+MMF+
etanercept
4/
day +150
day +157
day +164
day +169
0.7 x 106/kg
0.7 x 106/kg
0.7 x 106/kg
0.7 x 106/kg
Partial response
temporary
Skin and liver grade II
Steroid slow and partial tapering GVHD smooth recovery
after sirolimus introduction
5A Acute skin grade II Steroid+
etanercept+
CsA
1/
day +43
1.2 x 106/kg Complete response
definitive
No GVHD
CsA stopped 18 days after MSC
infusion, steroid tapering
New GVHD reflair 46 days after
MSC infusion, in chronic form
Alive, no GVHD
5B Chronic skin GVHD grade I Steroid 1/
day + 94
1.2 x 106/kg No response
Skin GVHD grade I
None Reintroduction of steroid,
MMF and etanercept. Slow
complete response
GVHD indicates graft-versus-host disease; CsA, cyclosporine A; MMF, mycophenolate mofetil; ECP, extracorporeal photopheresis.
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Biol Blood Marrow Transplant 16:1293-1301, 2010 1297PL-Expanded MSCs for GVHD Treatmentand inability to grow without anchorage in a semisolid
fluid. Cell lots were cryopreserved and thawed right
before patient intravenous infusion.
Immune Monitoring: Sample Collection and
Cytokine Plasma Level Detection
After having obtained an informed consent, blood
samples were collected from 4GVHDpatients infused
with MSCs. Plasma samples were obtained by centri-
fugation within 24 hours from blood collection. Tu-
mor necrosis factor (TNF)-a and inteferon (IFN)-g
plasma levels were assessed using commercial ELISA
kits (eBioscience, SanDiego, CA, USA, detection limit
5 4 pg/mL).RESULTS
Three hundred million mononucleated cells were
isolated from the washouts of the BM collection bags
and filters of a single donor. Mononucleated cells,
plated at 800  103 cells/cm2 in complete medium,
generated in 2weeks a subconfluent layer (80% conflu-
ence) of 15  106 cells with a fibroblastic-like shape.
Cells were frozen in multiple vials and, after all the
quality controls were adequately performed and
checked, cells were thawed and plated in complete me-
dium at 100 to 200 cell/cm2 for a further 2-week ex-
pansion in 5 different productions. Finally, overall,
we obtained 1780  109 cells frozen in 70 vials of
around 25  106 cells each vial, ready to be infused.
For more details on cell expansion methods and
quality control methods, see Capelli et al. [15].
Twenty-one MSC infusions were given to 11
patients; 4 patients received a single infusion, whereas
7 had 2 to 5 infusions. The median dose was 1.2 106/
kg (range: 0.7-3.7 106/kg). No patient had acute side
effects either during or after infusion, and none had
late side effects, so far, at a median follow-up of
8 months (range: 4-18 months). Median time from
HSCT to MSC treatment was 95 days (range:
34-300 days).
Fifteen of 21 MSC infusions induced either a com-
plete or a partial response in 8 of 11 patients. More-
over, all responding patients were able to eventually
taper ongoing immunosuppressive treatment after
MSC infusion. Details on patients’ treatment and re-
sponse to MSCs are resumed in Table 2a and 2b.
None of our patient presented GVHD progression
upon MSC administration, but patients 1, 2, 5, and 8
presented a GVHD recurrence 2 to 5 months after
MSC infusion. Overall response in our patients was
71.4%, with complete response in 23.8% and partial
response in 47.6%. Eight of 11 treated patients are
alive and in complete remission (CR) from their hema-
tologic disease with a median follow-up of 10 months
from HSCT (range: 6 to 24 months) and of 8 months
Figure 1. Time-based monitoring of TNF-a and IFN-g levels in patients treated with mesenchymal stromal cells (MSCs) (A, B): plasma levels of TNF-
a and IFN-g in patients with graft-versus-host-disease (GVHD) were monitored at different time points after MSC infusion. Monitoring of 2 patients is
shown. The GVHD of those patients was limited to the skin and GVHD score is expressed as overall grading.
1298 Biol Blood Marrow Transplant 16:1293-1301, 2010G. Lucchini et al.from MSC infusion (range: 4-18 months). Patient
number 8 died from GVHD progression and lung
aspergillosis on day 1329 after HSCT, patient num-
ber 9 died of sepsis on day 1126 after HSCT, and
patient number 11 died of GVHD progression and
lung infection on day 156 after HSCT. Currently,
5 patients are free from GVHD (2 of them with skin
cGVHD did not benefit from MSC, but later re-
sponded to further treatment), whereas patient num-
ber 1 has developed a skin and mucosal vGVHD
(grade II overall), which still needs treatment with
oral steroids andMMF. Patient 2 has developed a cuta-
neous cGVHD (grade I overall), which still requires
FK506 oral and topic treatment. Patients 3, 4, 5, 6,
7, and 10 are alive and well, without any ongoing im-
munosuppressive treatment.
As far as concerns immune monitoring of MSC
treatment, patient 5, who was suffering from a grade
II skin aGVHD, had a complete definitive response
to the first MSC infusion, as assessed by clinical obser-
vations (Figure 1A). TNF-a levels, which resulted ele-
vated before MSC infusion (mean concentration 5
253 pg/mL), persistently decreased (mean decrease 5
2.3-fold) starting 24 hours after treatment. IFN-g
levels diminished 2.9-fold if compared to the preinfu-sion values. Interestingly, upon GVHD reflair in
chronic form on day 194 after HSCT, the patient
received a further MSC infusion. cGVHD did not
respond to MSC treatment and TNF-a and IFN-g
plasma levels remained stable or even increased after
the infusion, although 4 lines of treatment were added.
After a transient decrease, TNF-a levels showed a pro-
gressive increase when compared to levels at GVHD
resolution on day 55. Accordingly, IFN-g levels
showed a stable increase (4.4 times) compared to levels
observed at disease resolution. Patient 7 (Figure 1B)
was treated in the presence of acute skin grade I
GVHD, that was persistent after introduction of i.v.
steroid. He presented a complete definitive response
after receiving 2 MSC infusions. After MSC adminis-
tration, TNF-a and IFN-g plasma levels remained sta-
ble and finally decreased, allowing a simultaneous
steroid tapering.DISCUSSION
The present study underlines the feasibility of
MSC administration on top of multiple lines of
immunosuppressive therapy in pediatric patients with
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the particular issue of GVHD treatment in children.
Although GVHD is less common in children than
adults, long-term side effects of prolonged immuno-
suppressive treatment is a major issue in the pediatric
setting. It is therefore of the utmost importance to pro-
pose a treatment strategy that may be able to reduce
the burden of conventional immunosuppression. In
our study, MSC administration proved its efficacy in
more than half of the treated patients and allowed
the tapering of other treatment lines.
MSC infusion caused a complete GVHD remis-
sion in 23.8% of our patients and a partial response
in 47.6% of cases. Other groups reported a higher
rate of CR (Le Blanc et al. [5] 55% complete response,
16% partial response). Isolated skin was the mostly in-
volved organ and mainly responded (at various degree)
in the aGVHD phase (3 of 4 patients). Similar results
in the treatment of skin GVHD were reported by
von Bonin and colleagues [11] when using PL-
expanded MSCs. This is relevant because other stud-
ies, including a phase III randomized one [16],
declared the inefficacy of MSC for skin GVHD treat-
ment. Although our and von Bonin et al. studies num-
ber of treated patients is limited, it might be the case
that PL-expanded MSCs harbor different trafficking
properties, which allow a better chemotaxis toward
the skin flogistic environment. This hypothesis needs
further investigations to acquire scientific robustness.
On the other hand, the same prochymal product,
which was declared ineffective for skin GVHD treat-
ment in a phase III randomized study [16], obtained
a 47% rate of response in skin GVHD in a pediatric
cohort of patients [13]. Younger patients may be,
therefore, more prone to respond to this kind of treat-
ment, either for peculiarities in their immunologic set-
ting or for higher infused MSC dosages.
In our hands MSC did not prove their efficacy in
isolated skin cGVHD with hyperchromic and
lichenoid characteristics (partial response in 2 and no
response in other 2 patients). In our limited cohort
of patients, which was treated with delay and after
other lines of immunosuppression, GVHD character-
istics (aGVHD versus cGVHD) may have represented
the first issue in influencing the patient response. For
instance, patient number 5 who received 2 treatments
with MSCs for 2 different GVHD flairs (the first with
an aGVHD pattern, the second with a cGVHD
pattern) responded to the first, but not to the second
infusion, thus supporting this hypothesis.
These data are in line with ongoing studies under-
lining the different mechanisms of action of MSC in
the acute and chronic phases of GVHD. It is probable
that MSCs need to be licensed by an inflammatory
environment, which is much more common in the
aGVHD setting than in the cGVHD setting. aGVHD
is characterized by inflammatory responses, duringwhich the production of several pro-inflammatory cy-
tokines (eg, IFN-g, IL-1, TNF-a) enhances the ability
of donor T lymphocytes to attack host tissues and to
produce more pro-inflammatory cytokines. On the
contrary, cGVHD is associated with a polarized TH-
2 state, which is consistent with the clinical manifesta-
tions of cGVHD in both human and animal models
(elevated IL-5 with eosinophilia, IL-4 with sclero-
derma), and whichmay weaken the efficacy ofMSC in-
fusion. Indeed, several articles have reported that the
inflammatory milieu is crucial for inducing the immu-
nosuppressive activity of MSC [17]. In particular, Pol-
chert and colleagues [18] demonstrated that IFN-g is
required to trigger the initial MSC effect. Recipients
of IFN-g–/– T cells did not respond to MSC treat-
ment and succumbed to GVHD. IFN-g pretreated
MSCs became immediately active and could suppress
GVHDmore efficiently than nontreated ones. Activa-
tion ofMSC by IFN-g induced the production of large
amount of immunosuppressive cytokines, adhesion
molecules, and chemokines, which attract and inhibit
T lymphocytes. This phenomenon was amplified in
the presence of TNF-a and IL-1 [19,20]. This could
explain why MSCs are more active in aGVHD than
in cGVHD.
Our data suggest a reduced efficacy of MSCs when
applied in severe gut GVHD (2 partial responses and 2
nonresponses with further GvHDprogression in 3 of 4
cases). Our data do not allow to draw any relevant con-
sideration on MSC efficacy for liver GVHD, because
of the limited number of cases (2 cases). The present
article underlines that the same patients may respond
differently to MSC infusion at different time points
of their clinical history.
Several studies have demonstrated that plasma pro-
teins involved in multiple processes such as T cell allo-
reactivity, inflammation, and tissue damage and repair,
are altered in patients with GVHD. We analyzed
plasma levels of TNF-a and IFN-g, 2 cytokines
crucially involved in GVHD pathogenesis [21-23], in
4 patients before and after MSC treatment. Not all
patients’ samples were analyzed because of the
complex immunosuppressive schedule of treatment
that most of them were receiving. We chose the
4 patients with the most linear pattern of immun-
osuppression to theoretically obtain more reliable
and analyzable data. The levels of TNF-a and IFN-g
were elevated before MSC infusion, transiently
decreased in nonresponder patients, and persistently
decreased in responder patients, correlating and
supporting the clinical data. In the other 2 tested
patients, no relevant cytokine modification was
observed, but it is noteworthy that they had a quite
complex scheme of multidrug therapy that may have
influenced the biologic data independently from
MSC infusion, thus impairing the robustness of the
analysis.
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sial, because recent results of late-stage clinical trials
sponsored by Osiris go in a different direction com-
pared with what previously published by Le Blanc
and colleagues [5], particularly for skin GVHD. In
the Osiris report, even though a significant improve-
ment was observed for liver and gut steroid-
refractory GVHD (P 5 .02 and .018, respectively),
no relevant amelioration was registered for skin
GVHD. Many issues should be considered to justify
such differences with previously published data. As
reported by Nature (http://www.nature.com/news/
2009/090909/full/news.2009.894.html), the prochy-
mal drug may work in certain subsets of patients and
it probably depends on GVHD localization and rapid-
ity of MSC use (earlier stage). Other major concerns
have to be considered. First, a pediatric population
(such as the one considered in the present study) may
be more prone to respond. Patients enrolled in the
Osiris trial were mostly adults, but in the pediatric co-
hort of 28 patients, prochymal showed a strong trend
of improvement in response rates. Certainly, Osiris
trials were much larger than our and Le Blanc’s
studies, as they included placebo groups and were dou-
ble blinded. This gives statistical robustness to their
results. The first study included 192 patients and the
second 260. In neither of them did any patient live
longer when compared with the placebo group. These
observations are, in our opinion, a confirmation that
MSCs may not be considered a curative option for
GVHD of any stage and organ. At any rate, their activ-
ity has been demonstrated at various levels, and the
preliminary results of the phase III prochymal study
are encouraging for steroid-refractory liver and gut
GVHD [16].
We emphasize here that, even if GVHD in some of
our patients was not graded higher than I overall, at the
time of MSC administration, all patients were already
receiving 3 to 5 lines of treatment, without any sign of
GVHD improvement before MSC infusion. Because
our study describes patients treated with MSCs under
compassionate use, the treatment schedule was tai-
lored for each patient based upon clinical needs, and
multiple doses ofMSCwere infused in a single patient,
either to prevent GVHD reflaring after immunosup-
pressive therapy tapering, or to retreat new flairs of
previously responsive GVHD. For the same reason,
we did not treat with multiple MSC infusions the first
2 reported patients. Despite their partial response, we
considered that they were far from transplantation, al-
ready receiving multiple lines of immunosuppression
and exhibiting a pattern of cGVHD, thus being likely
less prone to receive any benefit fromMSC treatment.
To our knowledge, no evidence has been produced
about the ideal timing and doses of MSC infusions in
the setting of GVHD treatment. Nevertheless, multi-
ple infusions are commonly reported in the literature[5]. Our patients responded to a median dose of 1.2
 106/kg MSC, which can be considered a low cell
dose in comparison to other published data [12].
This may suggest that, in the pediatric setting, re-
peated administrations might be more effective than
single high-dose MSC administration, although such
a theory deserves further studies. Also, recently
published observations [13] seem to corroborate this
hypothesis, particularly in the pediatric setting.
The present study also underlines the safety of
MSC use in children. None of the treated patients,
who already had been exposed to multiple lines of
treatment and intensive chemotherapy regimens, pre-
sented acute reactions to MSC infusion. Following
MSC administration we did not register any infectious
complication, including bacterial, fungal, and viral dis-
eases. This was also reported by other studies and the
different activity of MSC on alloantigens and virus-
specific T cell response has recently been investigated
by Karlsson et al. [24]. Moreover, no disease recur-
rence or second malignancies has been observed up
to now in our cohort.
Last, but not least, our present data underline the
importance to produce MSCs as cellular ‘‘drugs,’’ un-
der strict GMP conditions in an authorized laboratory,
using PL as a growth-promoting factor instead of FBS.
PL-medium, besides avoiding the use of animal-
derived material, accelerates MSC expansion reducing
the duration of ex vivo manipulation and therefore the
possibility of microbial contamination. As we previ-
ously described in detail [25,26], MSC growth in 5%
PL is superior to 10% FBS in terms of cell
proliferative capacity. PL lots have been standardized
in their platelet concentration, which has been
previously demonstrated to be the most relevant
element for the release of growth factors. In Salvade`
et al. [26], we analyzed differences in the release of
growth factors possibly responsible for the accelerated
growth rate. ELISA tests were performed to determine
the amounts of epidermal growth factor (EGF), tumor
growth factor (TGF)-b1, platelet-derived growth
factor (PDGF)-aa, PDGF-bb, vascular endothelial
growth factor (VEGF), and basic figroblast growth fac-
tor (FGF), well known in the literature to induceMSC
proliferation. We observed that all PL lots contain
a great quantity of the above-mentioned growth fac-
tors, particularly if compared to human plasma, whose
GF levels were undetectable. Certainly, such great
amount of growth factors detected in the PL-medium
is somehow responsible for accelerated MSC prolifer-
ation, but further studies are necessary to determine
which ones are truly relevant in promoting MSC
growth .
The GMP-grade production of an MSC bank
presents the double advantage of having a certified
product that respects already established well-defined
release criteria (which ensure the high quality of the
Biol Blood Marrow Transplant 16:1293-1301, 2010 1301PL-Expanded MSCs for GVHD Treatmentcell product), and also of establishing a third-party cell
bank, which allows the immediate use of defined num-
bers of identical vials in case of clinical need, starting
from the same donor. This latest observation should
ensure in the future a wider (and more rapid) use of
MSCs and an easier evaluation of their clinical effects
in larger studies.
The results of the present study induced us to open
a trial in pediatric patients in which 2 doses of
PL-culturedMSCs (1 106/kg dose at a 5-7-day inter-
val)will be administered as an early treatment of steroid-
resistant GVHD (EudraCT number 2008-007869-23).
This strategy will allow us to have amore homogeneous
population and to possibly observe real benefits of
a more prompt use of MSCs as a second-line treatment
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